Skip to main content
NVDA-4.34%AAPL+0.64%GOOGL-3.40%MSFT-2.04%AMZN-4.91%TSM-4.72%SPCX-9.14%META-8.04%AVGO-4.04%TSLA-2.70%LLY+2.83%BRK-B+1.86%MU-5.63%SKHY-6.99%WMT+2.33%JPM-0.01%AMD-7.87%V+1.14%XOM-0.18%JNJ+4.28%ASMLa-4.74%MA+1.15%ABBV-0.05%INTC-7.39%COST+1.51%CVX-0.07%0700.HK-2.89%1398.HK-1.34%CSCO-2.08%KO+2.42%PG+6.08%ORCL-3.70%UNH+1.81%BAC+0.42%1816.HK-0.22%3988.HK-1.80%HD+3.69%CAT-5.31%0005.HK-1.23%HSBA.L-2.45%PM+1.63%AP2d-6.79%0857.HK-0.82%AMAT-7.27%1288.HK-0.30%GE-1.48%0939.HK-0.61%NVS+1.49%LRCX-11.43%MS-1.87%PLNJPY-1.37%EURAUD-1.18%EURCAD-1.15%AUDUSD+0.99%USDCAD-0.95%EURJPY-0.88%GBPZAR+0.87%USDTHB+0.84%USDZAR+0.83%SGDJPY-0.80%CHFSEK+0.73%EURNZD-0.72%USDJPY-0.72%EURGBP-0.72%EURZAR+0.68%EURCHF-0.60%USDPLN+0.59%AUDCHF+0.57%NZDUSD+0.56%CADCHF+0.55%GBPUSD+0.54%AUDNOK-0.52%EURNOK-0.48%CHFSGD+0.47%NOKJPY-0.46%GBPAUD-0.46%AUDNZD+0.45%GBPCAD-0.45%EURPLN+0.45%USDCHF-0.42%NZDCAD-0.41%GBPTRY+0.41%USDNOK-0.33%CHFJPY-0.33%GBPHKD+0.32%AUDJPY+0.31%NZDSGD-0.31%GBPMXN-0.28%CADJPY+0.26%EURHKD-0.26%USDSEK+0.26%USDMXN+0.21%USDTRY+0.21%USDCNH-0.19%AUDSGD-0.19%EURUSD-0.18%NZDJPY-0.18%GBPJPY-0.18%USDILS+0.16%EURCNH-0.14%EURSGD-0.13%CHFNOK+0.13%USDHKD-0.13%USDDKK+0.13%NZDCHF+0.12%EURSEK+0.12%NZDMXN-0.11%GBPCHF+0.11%AUDDKK-0.06%EURCZK+0.05%USDCOP-0.04%GBPNZD-0.04%GBPSGD+0.04%AUDCAD+0.04%EURDKK-0.01%USDSGD+0.01%XAGUSD-5.56%GAGUSD-5.56%XPTUSD-3.68%HG1-2.78%UKOIL+2.63%XAUUSD-2.61%GAUUSD-2.61%USOIL+1.68%XNGUSD+0.22%COFFEE0.00%COCOA0.00%C10.00%BTCUSD-3.19%ETHUSD+16.36%USDTUSD-0.02%XRPUSD+9.91%SOLUSD+10.75%TRXUSDT-0.69%ZECUSDT-7.41%DOGEUSD+14.39%XMRUSDT-1.67%LINKUSD+14.52%XLMUSD-4.17%BCHUSDT-4.06%LTCUSD+8.69%UNIUSD-5.80%SUIUSD-4.86%HBARUSDT-5.25%TONUSD+26.39%TAOUSDT-5.16%AAVEUSD-5.65%DOTUSDT-2.26%WLDUSDT-3.44%ICPUSDT-5.70%ONDOUSDT-6.80%ARBUSDT-3.97%JUPUSDT-5.47%ATOMUSDT-2.35%INJUSDT-6.43%STXUSDT-10.30%TIAUSDT-6.07%FETUSDT-5.88%PYTHUSDT-6.57%SEIUSDT-7.66%IMXUSDT-7.27%GRTUSDT-5.52%OPUSDT-7.98%WIFUSDT-6.52%IOTAUSDT-4.34%AXSUSDT-5.26%POLUSDT-4.48%FARTCOINUSDT-5.03%EOSUSDT-0.39%DYDXUSDT-5.79%GALAUSDT-5.09%ORDIUSDT-2.72%RONINUSDT-3.56%NOTUSDT-4.94%NVDA-4.34%AAPL+0.64%GOOGL-3.40%MSFT-2.04%AMZN-4.91%TSM-4.72%SPCX-9.14%META-8.04%AVGO-4.04%TSLA-2.70%LLY+2.83%BRK-B+1.86%MU-5.63%SKHY-6.99%WMT+2.33%JPM-0.01%AMD-7.87%V+1.14%XOM-0.18%JNJ+4.28%ASMLa-4.74%MA+1.15%ABBV-0.05%INTC-7.39%COST+1.51%CVX-0.07%0700.HK-2.89%1398.HK-1.34%CSCO-2.08%KO+2.42%PG+6.08%ORCL-3.70%UNH+1.81%BAC+0.42%1816.HK-0.22%3988.HK-1.80%HD+3.69%CAT-5.31%0005.HK-1.23%HSBA.L-2.45%PM+1.63%AP2d-6.79%0857.HK-0.82%AMAT-7.27%1288.HK-0.30%GE-1.48%0939.HK-0.61%NVS+1.49%LRCX-11.43%MS-1.87%PLNJPY-1.37%EURAUD-1.18%EURCAD-1.15%AUDUSD+0.99%USDCAD-0.95%EURJPY-0.88%GBPZAR+0.87%USDTHB+0.84%USDZAR+0.83%SGDJPY-0.80%CHFSEK+0.73%EURNZD-0.72%USDJPY-0.72%EURGBP-0.72%EURZAR+0.68%EURCHF-0.60%USDPLN+0.59%AUDCHF+0.57%NZDUSD+0.56%CADCHF+0.55%GBPUSD+0.54%AUDNOK-0.52%EURNOK-0.48%CHFSGD+0.47%NOKJPY-0.46%GBPAUD-0.46%AUDNZD+0.45%GBPCAD-0.45%EURPLN+0.45%USDCHF-0.42%NZDCAD-0.41%GBPTRY+0.41%USDNOK-0.33%CHFJPY-0.33%GBPHKD+0.32%AUDJPY+0.31%NZDSGD-0.31%GBPMXN-0.28%CADJPY+0.26%EURHKD-0.26%USDSEK+0.26%USDMXN+0.21%USDTRY+0.21%USDCNH-0.19%AUDSGD-0.19%EURUSD-0.18%NZDJPY-0.18%GBPJPY-0.18%USDILS+0.16%EURCNH-0.14%EURSGD-0.13%CHFNOK+0.13%USDHKD-0.13%USDDKK+0.13%NZDCHF+0.12%EURSEK+0.12%NZDMXN-0.11%GBPCHF+0.11%AUDDKK-0.06%EURCZK+0.05%USDCOP-0.04%GBPNZD-0.04%GBPSGD+0.04%AUDCAD+0.04%EURDKK-0.01%USDSGD+0.01%XAGUSD-5.56%GAGUSD-5.56%XPTUSD-3.68%HG1-2.78%UKOIL+2.63%XAUUSD-2.61%GAUUSD-2.61%USOIL+1.68%XNGUSD+0.22%COFFEE0.00%COCOA0.00%C10.00%BTCUSD-3.19%ETHUSD+16.36%USDTUSD-0.02%XRPUSD+9.91%SOLUSD+10.75%TRXUSDT-0.69%ZECUSDT-7.41%DOGEUSD+14.39%XMRUSDT-1.67%LINKUSD+14.52%XLMUSD-4.17%BCHUSDT-4.06%LTCUSD+8.69%UNIUSD-5.80%SUIUSD-4.86%HBARUSDT-5.25%TONUSD+26.39%TAOUSDT-5.16%AAVEUSD-5.65%DOTUSDT-2.26%WLDUSDT-3.44%ICPUSDT-5.70%ONDOUSDT-6.80%ARBUSDT-3.97%JUPUSDT-5.47%ATOMUSDT-2.35%INJUSDT-6.43%STXUSDT-10.30%TIAUSDT-6.07%FETUSDT-5.88%PYTHUSDT-6.57%SEIUSDT-7.66%IMXUSDT-7.27%GRTUSDT-5.52%OPUSDT-7.98%WIFUSDT-6.52%IOTAUSDT-4.34%AXSUSDT-5.26%POLUSDT-4.48%FARTCOINUSDT-5.03%EOSUSDT-0.39%DYDXUSDT-5.79%GALAUSDT-5.09%ORDIUSDT-2.72%RONINUSDT-3.56%NOTUSDT-4.94%
AT

Allogene Therapeutics, Inc. (ALLO)

NASDAQ • Healthcare

$1.33
+$0 (+0.0%)
Market open

Last close at October 21, 2026 at 20:00 UTC

Open$1.33
Previous Close$1.33
Day Range$1.31 - $1.37
Avg. Volume (3M)5.6M
Market Cap$446.2M
52 Week Range
$1.04$4.46
Next EarningsIn 14 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$4.6M100%
Gross Profitminus cost of goods$4.6M100%

Fundamentals & Financials

Revenue (TTM)
$4.6M
Net Income (TTM)
-$165.4M
EPS (TTM)
-$0.67
ROA (TTM)
-30.08%
Current Ratio
10.72

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+32.0%Q1 2026-$0.17
+5.3%Q2 2026-$0.18
+24.1%Q3 2026-$0.13
Next

Nov 5

in 14 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +24.1%

Allogene Therapeutics' EPS of -$0.13 topped the -$0.17 estimate, +24%, in the fiscal second quarter of 2026 reported on August 12, as revenue and gross profit both came in at about $4.6 million. Operating loss was about $46.9 million, and net income was a loss of about $42.7 million versus a loss of about $50.9 million a year ago, +16.2% year over year; EPS was up 43.5% from -$0.23 a year earlier. For the next period, consensus calls for EPS of -$0.15 on revenue of $2,222.00.

Next report — what to expect

Allogene Therapeutics, Inc. (ALLO) reports earnings on November 5, 2026. Wall Street’s next-period consensus calls for EPS of -$0.147 on revenue of $2,500.00. Heading into the print, ALLO has beaten EPS in 7 of 8 most recent quarters, making any deviation from that pattern a key item to watch.

View full earnings history

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage biotechnology company focused on immuno-oncology, developing genetically engineered allogeneic T-cell therapies for cancer. In qualitative terms, it is an early-stage biotech built around off-the-shelf cell therapy candidates for hematologic and solid tumors rather than marketed products.

Name
Allogene Therapeutics, Inc.
CEO
Zachary Roberts
Website
www.allogene.com
Industry
Healthcare
Year Founded
2017
Employees
151

Today's Snapshot

AI-generated

ALLO is trading 5.3% below yesterday's close, against a firmer sector. ALLO is due to report earnings on 5 November.

Trading Volume

Below 10d avg (5.7M)

3.4M

vs S&P 500 Today

Strong Underperformance

-4.30%

Updated: October 22, 2026 at 16:50 UTC

ALLO Headlines

Biotech, Pharma Stocks Draw Fresh Valuation Focus

April 2, 2026

4 min read
View All News

Technical Indicators

1 Buy2 Neutral5 Sell
ALLO shows a pronounced bearish alignment: price sits beneath nearly all moving averages, including the 200-day, while the ADX is sharply elevated, indicating a strong directional move to the downside. Momentum and MACD are weak and on-balance volume is negative, which together confirm selling pressure, and intraday references like VWAP and pivot levels lie above the market. The RSI and Williams %R are deeply oversold, suggesting short-term exhaustion, yet the prevailing structure remains bearish and volatility is relatively high. Technical takeaway: Strong Sell — dominant bearish trend and distribution outweigh oversold oscillators.
All signals
  • EMA (5 indicators)$1.34 - $1.81
    Sell
  • RSI (14)25.99
    Buy
  • Stochastic %K (14, 3, 3)22.92
    Neutral
  • MACD Level (12, 26)-0.12
    Neutral

Peers & Related Assets

FATEFate Therapeutics, Inc.
$2.07+0.5%
AUTLAutolus Therapeutics plc
IPSCCentury Therapeutics, Inc.
DTILPrecision BioSciences, Inc.
CLLSCellectis S.A.
ATRAAtara Biotherapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.